Company intelligence / Profile preview

Biomage

United Kingdom

Ownership: Private
Development stage: Other

Overview

Biomage created Cellenics®, a cloud-based single-cell RNA-seq data analysis platform that accelerates drug discovery and identification of new drug targets by enabling biologists to perform complex bioinformatic analyses without code. Their technology has shortened research timelines and democratized single-cell data analysis. The company was acquired by Parse Biosciences and the Cellenics instance has been rebranded as Trailmaker[5][2].

Industry: Drug Discovery Services

Partnerships

Harvard Medical School

Beyond the preview

Go deeper on Biomage.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomage.

Explore the full profile